article · Journal of Infection

Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial

Chijioke Bennett
Faeezah Patel
Zaheer Hoosain
Gabriella Benadé
Umesh Lalloo
Shirley Galbiati
Cheryl Louw
Anthonet Koen
Vongane Louisa Maluleke
Vivek Shinde
Esme Louise Venter
Shabir A. Madhi

20242 citationsOpen accessUniversity of the Witwatersrand

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

This study demonstrated that NVX-CoV2373 produced consistent immunogenicity responses to SARS-CoV-2 among PLWH and HIV-uninfected participants, with no new safety signals.

Research topics

SARS-CoV-2 and COVID-19 Research
Vaccine Coverage and Hesitancy
Virology and Viral Diseases

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1016/j.jinf.2024.106285

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.